What is NETRIS Pharma?
Headquartered in Lyon, France, NETRIS Pharma operates as a specialized clinical-stage immuno-oncology enterprise integrated within a premier cancer research ecosystem. The company distinguishes itself through the development of first-in-class therapeutics specifically engineered to target Netrin-1. By addressing the critical issue of resistance in oncology treatments—including chemotherapy, targeted therapy, and immunotherapy—NETRIS Pharma provides a vital bridge for patients who have exhausted conventional options. Their proprietary intellectual property portfolio and strategic research alliances serve as the foundation for their high-impact clinical initiatives.
How much funding has NETRIS Pharma raised?
NETRIS Pharma has raised a total of $8.4M across 1 funding round:
Unspecified
$8.4M
Unspecified (2026): $8.4M with participation from Horizon Europe
Key Investors in NETRIS Pharma
Horizon Europe
A major research and innovation funding program by the European Union that supports high-impact scientific projects and clinical advancements across the continent.
What's next for NETRIS Pharma?
With the recent infusion of capital, NETRIS Pharma is poised to transition into a more aggressive phase of clinical validation. The strategic focus will likely center on expanding the reach of its Netrin-1 targeting platform, potentially initiating new trials to address broader oncology indications. As the company scales its operations, the emphasis will remain on leveraging its unique research capabilities to overcome therapeutic resistance, thereby enhancing patient outcomes and increasing the long-term value of its clinical pipeline. This phase of growth is critical for establishing the company as a cornerstone of modern cancer care.
See full NETRIS Pharma company page
